Title : Phase III study of molecularly targeted adjuvant therapy in locally advanced urothelial cancer of the bladder based on p53 status.

Pub. Date : 2011 Sep 1

PMID : 21810677






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 INTRODUCTION: Retrospective studies suggest that p53 alteration is prognostic for recurrence in patients with urothelial bladder cancer and predictive for benefit from combination methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) adjuvant chemotherapy. Methotrexate tumor protein p53 Homo sapiens